Parkwood LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 255,717 shares of the company's stock after acquiring an additional 33,394 shares during the period. Sanofi accounts for about 1.4% of Parkwood LLC's holdings, making the stock its 17th largest position. Parkwood LLC's holdings in Sanofi were worth $12,333,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in SNY. Abel Hall LLC grew its holdings in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after buying an additional 194 shares during the last quarter. Providence Capital Advisors LLC grew its holdings in Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after buying an additional 201 shares during the last quarter. Keudell Morrison Wealth Management grew its holdings in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after buying an additional 217 shares during the last quarter. Bailard Inc. grew its holdings in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after buying an additional 220 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Price Performance
Shares of Sanofi stock traded up $0.82 during midday trading on Friday, hitting $51.68. 2,724,204 shares of the company were exchanged, compared to its average volume of 2,374,732. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market cap of $130.56 billion, a P/E ratio of 20.76, a PEG ratio of 1.01 and a beta of 0.55. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The firm has a 50 day simple moving average of $53.36 and a 200-day simple moving average of $51.90.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sanofi's revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the company earned $1.78 EPS. Research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is 57.14%.
Analysts Set New Price Targets
A number of analysts have issued reports on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $63.33.
Check Out Our Latest Research Report on SNY
Sanofi Company Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
